Jump Financial LLC Takes Position in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Jump Financial LLC purchased a new stake in Fulgent Genetics, Inc. (NASDAQ:FLGT - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 25,300 shares of the company's stock, valued at approximately $467,000. Jump Financial LLC owned approximately 0.08% of Fulgent Genetics as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of FLGT. Geode Capital Management LLC raised its stake in Fulgent Genetics by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 514,152 shares of the company's stock valued at $9,499,000 after purchasing an additional 11,283 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Fulgent Genetics by 39.4% during the 4th quarter. JPMorgan Chase & Co. now owns 471,259 shares of the company's stock valued at $8,704,000 after buying an additional 133,215 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Fulgent Genetics by 14.0% during the 4th quarter. Invesco Ltd. now owns 181,714 shares of the company's stock worth $3,356,000 after acquiring an additional 22,301 shares during the last quarter. Barclays PLC grew its position in Fulgent Genetics by 3.2% in the fourth quarter. Barclays PLC now owns 180,397 shares of the company's stock worth $3,332,000 after acquiring an additional 5,542 shares in the last quarter. Finally, Trexquant Investment LP increased its stake in Fulgent Genetics by 47.0% in the fourth quarter. Trexquant Investment LP now owns 128,606 shares of the company's stock valued at $2,375,000 after acquiring an additional 41,147 shares during the last quarter. Institutional investors own 48.06% of the company's stock.

Analyst Ratings Changes

FLGT has been the subject of several research analyst reports. Piper Sandler dropped their price target on Fulgent Genetics from $22.00 to $16.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. StockNews.com upgraded Fulgent Genetics from a "sell" rating to a "hold" rating in a research report on Wednesday, March 5th.

Fulgent Genetics Price Performance

Fulgent Genetics stock traded down $0.28 during mid-day trading on Tuesday, hitting $18.25. The company's stock had a trading volume of 201,478 shares, compared to its average volume of 259,827. The business has a 50 day moving average price of $17.32 and a 200-day moving average price of $18.12. Fulgent Genetics, Inc. has a 12 month low of $14.57 and a 12 month high of $25.11. The stock has a market cap of $563.21 million, a price-to-earnings ratio of -3.29 and a beta of 1.36.

Insider Activity

In other news, CFO Paul Kim purchased 100,000 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was bought at an average cost of $15.96 per share, for a total transaction of $1,596,000.00. Following the acquisition, the chief financial officer now directly owns 348,282 shares of the company's stock, valued at $5,558,580.72. This represents a 40.28 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 31.76% of the stock is currently owned by corporate insiders.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.